Aptevo Therapeutics Inc APVO The shares rise on Wednesday.
According to data from Benzinga Pro, the share is higher with a strong volume of 81.8 million compared to the average volume of 275.3k.
What happened: Aptevo revealed new clinical data from the current phase 1b/2 Rainier study for evaluation of mipletamig, the first-in-class CD123 x CD3 biecespic antibody, in combination with standard-of-care Venetoclax and Azacitidine (Venza) for new diagnosted) Myeloid myeloid myeloid myeloid myeloid myeloid myeloid myeloid myelemia (AML) who his recipient of intensive chemotherapy.
During two investigations, the miplet triplet therapy delivered remissions to 85% of the evaluable front line AML patients, who exceed considerable results of competitive studies, including those that were achieved in the Viale A -Study that Venetoclax and Azacitine) as Doublet therapy.
One patient who was removed from study and successfully received a transplant.
Also read: Aptevo Therapeutics says that two extra patients reach remission within 30 days of treatment at an early stage of leukemia study
One CR patient did not have a minimal remaining disease (MRD-negative status) but had the genetic biomarker TP53, which is associated with resistance to chemotherapy and some targeted therapeutics.
These updated results of the Rainier Dose Expansion Trial show a mandatory efficacy advantage in addition to a strong safety profile.
No Cytokine delivery was observed in Cohorten 1 or 2.
Cohort 3 is approaching the full registration at the highest dose level so far evaluated in combination therapy.
Why it matters: AML remains an aggressive and difficult to treat blood cancer, especially for older or medically unsuitable patients, where treatment options are limited and the results are generally poor.
To date, the results of the Rainier study show the ever -impressive clinical profile of mipletamig, which emphasizes its potential as a differentiated, highly targeted immunotherapy with a mandatory safety profile.
In addition, APTEVO Therapeutics announced a registered direct range of $ 8 million on Wednesday.
The company offered 2,465 million shares or pre -financed warrants to buy up to 12.325 million for $ 3.25 per share and associated warrants.
The Warrants have a exercise price of $ 3.25 per share.
Price promotion: APVO shares have risen 137.2% at $ 6.69 at the last check on Wednesday.
Read next:
#MicroCap #Aptevo #stock #disorders #higher #Wednesday #Aptevo #Therapeutics #Nasdaq #APVO